Evidence map›Paper›PMID 35783542›Full record

ArticleIntegrative medicine research2022

Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): A randomized clinical trial.

Mohammad Setayesh, Mehrdad Karimi, Arman Zargaran, Hamid Abousaidi, Armita Shahesmaeili, Fatemeh Amiri, Fatemeh Sadat Hasheminasab

Open access · goldAbstract read
In one paragraph

Article in Integrative medicine research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Review
  3. Food science & nutrition · 2024
    Article
  4. Review
  5. Frontiers in pharmacology · 2024
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mohammad SetayeshDepartment of Traditional Medicine, School of Persian medicine, Kerman University of Medical Sciences, Kerman, Iran.
Mehrdad KarimiDepartment of Traditional Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Arman ZargaranDepartment of Traditional Pharmacy, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Hamid AbousaidiResearch Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran.
Armita ShahesmaeiliHIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health Kerman University of Medical Sciences, Kerman, Iran.
Fatemeh AmiriAfzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran.
Fatemeh Sadat HasheminasabPharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Kerman University of Medical Sciences · IRTehran University of Medical Sciences · IRZahedan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The global attention to the capacities of traditional medicine for alleviating the clinical manifestations of COVID-19 has been growing. The present trial aimed to evaluate the efficacy and safety of a Persian herbal medicine formula among patients with COVID-19. Methods: The present trial was conducted in Afzalipour hospital, Kerman, Iran, from June to September 2020. Hospitalized COVID-19 patients were randomly divided into intervention (Persian herbal medicine formula + routine treatment) or control (only routine treatment) groups. The intervention group received both capsule number 1 and 2 every 8 hours for 7 days. Capsule number 1 contained extract of the Results: Eighty-two patients were enrolled to the study, while 79 cases completed the trial and their data were analyzed (mean age: 59.1 ± 17.1 years). Based on the results, the Persian medicine formula decreased the mean hospitalization days, so that the mean difference of length of hospitalization as primary outcome was 2.95 ± 0.43 days. A significant clinical improvement was observed regarding dyspnea, need for O Conclusion: The present study supported the use of the Persian medicine formula as an adjuvant therapy for hospitalized COVID-19 patients. Study registration: Iranian Registry of Clinical Trials (www.irct.ir): IRCT20200330046899N1. Study registration: Iranian Registry of Clinical Trials (www.irct.ir): IRCT20200330046899N1.

Indexed as

COVID-19Glycyrrhiza glabraherbal medicineNigella sativaPersian medicineRheum palmatum

Identifiers

PMID35783542
PMCPMC9233882
OpenAlexW4281855590

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.